Protective effect of calcium dobesilate against early diabetic nephropathy of rat kidney

Yaoxue Xuebao

Volumn 44, Issue 2, 2009, Pages 126-133

  Mei juan, G A O ^a   Ming, L I U ^a   Bo, L I ^a   Ming long, L I ^a   Li xiang, Bian ^a   Gui na, Y U ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium dobesilate; Diabetic nephropathy; Endothelin; Matrix metalloprotein 9; Plasminogen activator inhibitor 1

Indexed keywords

ALBUMIN; CHOLESTEROL; DOBESILATE CALCIUM; ENDOTHELIN; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG DOSE COMPARISON; ELECTRON MICROSCOPE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VASCULAR ENDOTHELIUM; ALBUMINURIA; ANIMAL; BLOOD; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; RANDOMIZATION; ULTRASTRUCTURE; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; CALCIUM DOBESILATE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENDOTHELINS; HEMOGLOBIN A, GLYCOSYLATED; HEMOSTATICS; KIDNEY CORTEX; MALE; MATRIX METALLOPROTEINASE 9; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 64549117435     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study [J]. Clin J Am Soc Nephrol, 2006, 1: 761-767.
2. Yang YN. Clinical symptom and prospect for diabetic nephropathy [J]. Chin J Endocrinol 2002, 18: 225.
3. Casas JP, Chua W, Loukageorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis [J]. Lancet, 2005, 366: 2026-2033.
4. Suissa S, Hutchinson T, Brophy JM, et al. ACE- inhibitor use and the long-term risk of renal failure in diabetes [J]. Kidney Int, 2006, 69: 913-919.
5. Ribeiro ML, Seres Al, Carneiro AM, et al. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomized double-blind study [J]. Craefes Arch Clin Exp Ophthalmol, 2006, 244: 1591-1600.
6. Chung HK, Choi SM, Ann BO, et al. Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy [J]. Arzneimittelforschung, 2005, 55: 573-580.
7. Gauay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy [J]. Treat Endocrinol, 2005, 4: 221-232.
8. Chen LP, Zhou QL, Peng WS, et al. Effect of rosiglitazone on expressions of nephrin and podocin in diabetic rat's podocyte [J]. Chin J Nephrol 2007, 23: 263-264.
9. Li C. Disease Model and Experimental Pathology [M]. Jilin: Jilin University Press, 2002, 1: 20-23.
10. Chen LP, Zhou QL, Peng WS, et al. The protective effect of the combination of rosiglitazone and losartan on the podocytes of diabetic nephropathy rats [J]. J Prac Med 2007, 23: 1124-1126.
11. Phillips PJ, Phillipov G. Diabetes monitorin-albuminura- frequently asked questions [J]. Aust Fam Physician, 2007, 36: 713-715.
12. Rademacher E, Mauer M, Jacobs DR Jr, et al. Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients [J]. Clin J Am Soc Nephrol, 2008, 3: 998-1005.
13. Hargrove GM, Dufresne J, Whiteside C, et al. Diabetes mellitus increases endotheline-1 gene transcription in rat kidney [J]. Kidney Int, 2000, 58: 1534-1545.
14. Ha H, Lee HB. Reactive oxygen species and marx remodeling in diabetic kidney [J]. J Am Soc Nephrol, 2003, 14: 246.
15. Lee HS, Moon KC, Song CY, et al. Glycated albumin activates PAI-1 transcription through Smad DNA binding sites in mesangial cells [J]. Am J Physiol Renal Physiol, 2004, 287: 665-672.
16. Aucella F, Margaglione M, Vigilante M, et al. PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis [J]. Nephrol Dial Transplant, 2003, 18: 1142-1146.
17. Lee EA, Seo JY, Jiang Z, et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney [J], kidney Int, 2005, 67: 1762-1771.
18. Lassila M, Fukami K, Jandeleit-Dahm K, et al. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease [J]. Diabetologia, 2007, 50: 1315-1326.
19. Van Huyen JP.Viltard M, Nehiri T, et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 is altered during nephrogenesis in fetuses from diabetic rats [J]. Lab Invest, 2007, 87: 680-689.
20. Tryggvason K, Wareiovaara J. How does the kidney filter plasma? [J]. Physiology (Bethesda), 2005, 20: 96-101.
21. Chiang ML, Hawkins EP, Berry PL, et al. Diagnostic and prognostic significance of glomerular epithelial cell vacuolization and podocyte effacement in children with minimal lesion nephrotic syndrome and focal segmental glomerulosclerosis: an ultuastructural study [J]. Clin Nephrol, 1988, 30: 8-14.
22. Zou J, Yaoita E, Watanabe Y, et al. Upregulation of human nephrin mRNA in diabetic nephropathy [J]. Nephrol Dial Transplant, 2004, 19: 380-385.